Travelers swings to loss as it books $1.5 billion in catastrophe losses following tornadoes and hail storms
By Ciara Linnane
There were official catastrophe events on 88 of the 91 days of the quarter, says CEO
Travelers Cos. Inc.'s stock reversed its early losses to trade up 2% Thursday, after the insurer swung to a second-quarter loss as it was hit with $1.5 billion in catastrophe losses.
That was almost double the $746 million in catastrophe losses recorded in the year-earlier period, and was caused by numerous severe wind and hail storms in multiple states.
"This quarter we reported strong underlying results and investment returns, as well as net favorable prior year reserve development, which were essentially offset by an historic level of industry-wide catastrophe losses," Chief Executive Alan Schnitzer said in a statement.
On a call with analysts, Schnitzer said there were PCS-designated catastrophe events on 88 of the 91 days of the quarter. PCS, or Property Claim Services, is the authority on insured property losses from catastrophes in the U.S.
The company (TRV) had six events surpass the $100 million mark in the quarter, the most ever for a single quarter since it began disclosing the table in 2013, said Chief Financial Officer Daniel Frey on the call.
There were seven weather disasters in the U.S. in 2023 so far, according to the National Oceanic and Atmospheric Administration. These included severe flooding in California that started after Christmas and lasted into March, dumping rain and record snowfall in parts of the Sierra and Southern California.
That was followed by a cold wave in the Northeast in early February that downed trees and power lines in New England. The Southeast and Midwest were hammered by tornadoes and severe thunderstorms and hail in March and April.
See also: Heavy rains swamp Northeast again; at least 5 die in Pennsylvania flash flooding
New York-based Travelers posted a net loss of $14 million, or 7 cents a share, for the quarter, after income of $551 million, or $2.27 a share, in the year-earlier period.
The company's adjusted per-share earnings came to 6 cents, well below the $2.05 FactSet consensus.
Revenue rose to $10.098 billion from $9.136 billion a year ago, ahead of the $9.972 billion FactSet consensus.
Net written premiums rose 14% to $10.318 billion.
The company's underlying combined ratio, a measure of overall profitability, stood at 91.1%, down from 92.8% a year ago. The company's net prior year reserve development was $60 million pre-tax,
The company had an underwriting loss of $640 million, after a gain of $113 million a year ago. Net investment income rose 5% to $712 million.
The stock has fallen 9% in the year to date, while the Dow Jones Industrial Average has gained 6%.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-20-23 1446ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Paramount Earnings: CEO Has Gone, For-Sale Sign Is Up; Good Results Would’ve Been Nice to Learn
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure